Bausch & Lomb Corp [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	S-1/A	S-1
Revenues:
BELARUS	8	7	8
UKRAINE	7	12	14
Other	3,753	3,746	3,390
Total revenues [+]	3,768	3,765	3,412	3,778	3,665
Products				3,729	3,615
Other				49	50
Revenue growth [+]	0.1%	10.3%	-9.7%	3.1%
BELARUS	14.3%	-12.5%
UKRAINE	-41.7%	-14.3%
Ophthalmic Pharmaceuticals	-3.8%	-3.0%
Cost of goods sold	1,518	1,462	1,257	1,382	1,327
Gross profit	2,250	2,303	2,155	2,396	2,338
Gross margin	59.7%	61.2%	63.2%	63.4%	63.8%
Selling, general and administrative	1,478	1,389	1,253	673	609
Research and development	307	271	253	258	221
Other operating expenses	13	17	38	721	715
EBITDA [+]	587	749	730	865	793
EBITDA growth	-21.6%	2.6%	-15.6%	9.1%
EBITDA margin	15.6%	19.9%	21.4%	22.9%	21.6%
Depreciation and amortization	135	123	119	121
EBITA	452	626	611	744	793
EBITA margin	12.0%	16.6%	17.9%	19.7%	21.6%
Amortization of intangibles	244	292	323	348	377
EBIT [+]	208	334	288	396	416
EBIT growth	-37.7%	16.0%	-27.3%	-4.8%
EBIT margin	5.5%	8.9%	8.4%	10.5%	11.4%
Non-recurring items	1	5	28
Interest expense, net [+]	140		-3	-1
Interest expense	146
Interest income	6		3	1
Other income (expense), net [+]	6	-11	27	2	1
Gain (loss) on foreign currency transactions	6	-11	27
Pre-tax income	73	318	290	399	417
Income taxes	58	125	307	96	-302
Tax rate	79.5%	39.3%	105.9%	24.1%
Minority interest	9	11	1	-5	-9
Net income	6	182	-18	303	719
Net margin	0.2%	4.8%	-0.5%	8.0%	19.6%

Basic EPS [+]	$0.02	$0.52	($0.05)
Growth	-96.7%	-1111.1%
Diluted EPS [+]	$0.02	$0.52	($0.05)
Growth	-96.7%	-1111.1%

Shares outstanding (basic)	350	350	350
Growth	0.0%	0.0%
Shares outstanding (diluted) [+]	350	350	350
Growth	0.1%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.